LONDON, May 27 (Reuters) – AstraZeneca said on
Friday U.S. regulators would not approve its new drug for high
potassium levels at present due to a manufacturing issue,
dealing a blow to a product…
The post UPDATE 1-AstraZeneca potassium drug delayed by manufacturing snag appeared first on NASDAQ.